Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Completed1
Terminated1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed125%
terminated125%
unknown125%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686
terminatedphase_1

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

NCT02025881
completedphase_1

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

NCT02658214
unknownphase_2

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

NCT04254471

Clinical Trials (4)

Showing 4 of 4 trials
NCT05652686Phase 1

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Recruiting
NCT02025881Phase 1

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

Terminated
NCT02658214Phase 1

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Completed
NCT04254471Phase 2

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4